News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rib-X Pharmaceuticals, Inc.' RX-04 Program Will be Featured at Windhover Information Inc.'s Therapeutic Area Partnerships Meeting as a "Top 10 Infectious Diseases Project to Watch"


11/29/2012 9:51:54 AM

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today that the Company’s RX-04 program has been selected by Windhover Information as one of the “Top 10 Infectious Diseases Projects to Watch.” RX-04 is Rib-X’s most advanced preclinical program focused on using a discrete, novel binding site within the bacterial ribosome to design and develop completely new classes of antibiotics to treat some of the most deadly and difficult-to-treat, multi-drug resistant Gram-positive and Gram-negative infections. Data recently presented at ICAAC 2012 demonstrated the unique activity of RX-04 compounds across a diverse array of bacterial pathogens including against carbapenem- and colistin-resistant strains of Klebsiella pneumoniae and major biodefense pathogens.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES